2.5 mg retatrutide 5MG Retatrutide: The New Triple-Agonist Weight

Patients should be monitored for any exacerbation of gastrointestinal symptoms when using both medications concurrently

(DOCX 87 kb) Rights and permissions Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made

[DOI] [PubMed] [Google Scholar] 64.Lean MEJ, Leslie WS, Barnes AC, et al

This is a limitation of virtually every toxicology study that does not use analytical methods

The side effect comparison between the two also helps clarify their risk profiles